The earnings call reflected a cautious yet optimistic outlook, with strong cost management and improved DSA performance offsetting revenue declines across segments. While there are concerns about NIH funding and challenges in the Manufacturing segment, the company is optimistic about strategic investments and increased guidance.

Company Guidance -

Q2 2025

During the Charles River Laboratories First Quarter 2025 Earnings Conference Call, the company provided an updated financial guidance for the year. They raised their 2025 revenue guidance by 100 basis points to a 2.5% to 4.5% organic decrease and increased their non-GAAP earnings per share guidance by $0.20 at the midpoint, setting a new range of $9.30 to $9.80. This adjustment was primarily driven by better-than-expected DSA performance, where the net book-to-bill ratio returned to above 1x for the first time in over two years, indicating improved quarterly bookings. Despite a 2.7% decrease in revenue to $984.2 million for the first quarter, the operating margin improved to 19.1%, up 60 basis points year-over-year, supported by cost-saving initiatives and favorable mix. Additionally, the company generated approximately $112.4 million in free cash flow and repurchased $350 million in shares during the quarter.

Improved DSA Segment Performance

DSA net book-to-bill improved to 1.04x in the first quarter, the first time above 1x in over 2 years, due to improved bookings and a decline in study cancellations.

Strong Cost Savings and Margin Improvement

Operating margin increased by 60 basis points to 19.1% year-over-year, driven by cost savings from restructuring initiatives, contributing to EPS growth of 3.1%.

Increased Financial Guidance

Due to better-than-expected DSA performance, revenue guidance was raised by 100 basis points to a 2.5% to 4.5% decrease organically, and non-GAAP EPS guidance was increased by $0.20 at midpoint.

Growth in Small and Midsized Biotech Revenue

Revenue for small and midsized biotech clients grew for the second consecutive quarter, indicating resilience despite funding challenges.

Successful Strategic Investments

Continued expansion into NAMs with $200 million annual revenue from NAMs-related services, highlighting Charles River's investment in advanced in vitro toxicology, predictive immunotoxicology assays, and organ-on-a-chip platforms.

Charles River Labs (CRL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CRL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 06, 2025	2025 (Q2)	2.50 / -	2.8	―	―	―
May 07, 2025	2025 (Q1)	2.08 / 2.34	2.27	3.08% (+0.07)
Feb 19, 2025	2024 (Q4)	2.53 / 2.66	2.46	8.13% (+0.20)
Nov 06, 2024	2024 (Q3)	2.42 / 2.59	2.72	-4.78% (-0.13)
Aug 07, 2024	2024 (Q2)	2.39 / 2.80	2.69	4.09% (+0.11)
May 09, 2024	2024 (Q1)	2.06 / 2.27	2.78	-18.35% (-0.51)
Feb 14, 2024	2023 (Q4)	2.40 / 2.46	2.98	-17.45% (-0.52)
Nov 08, 2023	2023 (Q3)	2.36 / 2.72	2.63	3.42% (+0.09)
Aug 09, 2023	2023 (Q2)	2.64 / 2.69	2.77	-2.89% (-0.08)
May 11, 2023	2023 (Q1)	2.59 / 2.78	2.75	1.09% (+0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CRL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 07, 2025	$115.41	$136.97	+18.68%
Feb 19, 2025	$154.39	$165.00	+6.87%
Nov 06, 2024	$188.68	$214.20	+13.53%
Aug 07, 2024	$228.80	$199.96	-12.60%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.